Atezolizumab and bevacizumab are PD-L1 inhibitor and VEGF inhibitor, respectively, and a recent study of IMBrave150 trial indicated that comparing with sorafenib, atezolizumab in combination with bevacizumab improved overall response rate, overall survival and progression-free survival dramatically in patients with unresectable HCC (Finn et al., 2020b; Hack et al., 2020). The gene discussed is VEGFA; the disease is hepatocellular carcinoma.